Coherent Market Insights, a market intelligence and consulting company, has developed an easy to access database for companies interested in biologics and biosimilars. This database, called the PHASE-XS, includes complete clinical and market related data for respective molecules in phase 3 and 4. PHASE-XS helps you to stay updated with respect to the pipeline developments. Information related to trial design, current phase, patent expiry, indication, technology, therapeutic category, approved indications, end point analysis, research locations, dosage, physician-administered or self-administered, route of administration, update, reimbursement, addressable patient population, and more of key data is included in the PHASE-XS.
PHASE-XS, a market solution for biologics, includes clinical information about phase 3 and phase 4 products for biologics (excluding vaccines) and biosimilars.
So, if you are interested in knowing your competitor research design, biosimilar opportunity and product competition in near future, click on the below link for more details on PHASE-XS.
Benefits of PHASE-XS:
The database can be accessed through subscription service and is available in accessible format for the clients to decipher the data easily.
It is critical for a biopharmaceutical development company to analyze its competition as more and more companies are now gaining more interest in biopharmaceutical products. Several SMEs and start-ups are focusing on developing novel biopharma therapies for rare diseases, cancers, neurological diseases, and other chronic ailments. Moreover, generic players could eye for potential biological products going off-patent in the near future.
Subscribe to our newsletter to get notification about new updates,information, discount, etc..